Core Viewpoint - Guangyuyuan stated that its information disclosure is legal and compliant, with no undisclosed matters that should be announced, and all disclosed data is true, accurate, and complete [2] Group 1 - The company emphasized that its governance procedures are legal and compliant, and disclosures are timely, in accordance with the Articles of Association and relevant laws and regulations [2] - Guangyuyuan assured that its independence is guaranteed, and any related party transactions with the controlling shareholder will strictly follow relevant rules and compliance review procedures [2] - The company encouraged investors to make rational judgments and be aware of investment risks [2]

Core Viewpoint - Guangyuyuan (600771) aims to focus on "growth" as its core objective by 2025, with a performance-oriented approach to management and sales [1] Financial Performance - The company reported double growth in core indicators for the first, second, and third quarters of 2025 compared to the same periods in the previous year [1] - Key metrics such as net cash flow, accounts receivable, and sales expense ratio have shown varying degrees of improvement [1] Operational Improvements - The composition of sales expenses has been standardized and disclosed in regular reports, aligning with the company's goals and actual business performance [1] - The company is committed to enhancing its operational quality and governance capabilities by adhering to relevant management systems [1] Future Strategy - Despite current operational results being significantly below market expectations, the company plans to actively incorporate feedback and suggestions from stakeholders to refine operations and improve organizational structure [1] - The focus is on promoting sustainable and healthy development of the company [1]

Group 1 - The core viewpoint of the article is that Guangyuyuan (600771) has clarified its relationship with Beijing Futai Henglai Technology Co., Ltd., which is authorized to use its trademark for store operations [1] - The company emphasizes that the relationship with the licensee is based on product distribution and complies with regulatory approval procedures [1] - Guangyuyuan plans to strengthen brand authorization management, enhance daily supervision, conduct regular evaluations, and continue promoting brand standardization efforts to protect its brand image and interests [1]

Core Viewpoint - Guangyuyuan clarified that "Guangyuyuan brand Yiling Royal Wine" is not a product of the company, nor is it authorized or commissioned for production by the company, indicating a case of mislabeling by an online specialty store [1] Company Response - The company has taken immediate legal action, including investigation and complaint measures, to combat the infringement of its brand image [1]

Group 1 - The core point of the article is that Guangyuyuan's subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., has received approval from the National Medical Products Administration for the registration of Banxia Xiexin Decoction granules, making it the first company in the country to obtain this drug registration certificate [1] - The drug is classified as a Category 3.1 traditional Chinese medicine compound preparation, managed according to ancient classic prescriptions [1] - The company is currently preparing for the drug's market launch in accordance with relevant regulations, although the sales situation may be influenced by policy and market factors, leading to uncertainties [1]

Core Viewpoint - Guangyuyuan (600771) emphasizes its commitment to transparent and efficient communication with investors through the "Shanghai Stock Exchange e-Interaction" platform [1] Group 1 - The company has established a board office that regularly organizes and feeds back questions from the "Shanghai Stock Exchange e-Interaction" platform to all directors and senior management [1] - This process ensures that both the management and operational teams are fully aware of the information from the interaction platform [1] - All investors can access the content on this interaction platform, reinforcing the company's dedication to compliance and transparency in investor communication [1]

Group 1 - The company has received the Traditional Chinese Medicine Registration Certificate for "An Gong Niu Huang Wan" from the Macao SAR Government's Drug Regulatory Authority, allowing the product to be sold in Macao [1] - "An Gong Niu Huang Wan" is a classic traditional Chinese medicine with indications for clearing heat and detoxifying, used for conditions such as high fever, convulsions, and coma [1] - The product's traditional manufacturing technique has been included in the national intangible cultural heritage list [1] Group 2 - According to data from Minet, the sales revenue of "An Gong Niu Huang Wan" in Chinese urban and county-level public hospitals and online pharmacies is projected to be RMB 498,242 million in 2024 [2] - The approval for the product is expected to help the company expand its overseas market presence and enhance brand and product competitiveness, although it will not have a significant impact on the company's current performance [3] - The sales of the product are subject to national policies and market environment changes, indicating a degree of uncertainty [3]

Core Viewpoint - Company has received the Traditional Chinese Medicine registration certificate for "An Gong Niu Huang Wan" from the Macao government, which will allow the product to be sold in Macao, enhancing the company's overseas market presence and brand competitiveness [1][3]. Group 1: Product Information - The registered product is "An Gong Niu Huang Wan" with the registration number MAC-C00298, categorized as an over-the-counter traditional Chinese medicine [1]. - The product is manufactured by Shanxi Guangyu Yuan Guoyao Co., Ltd., located in Jinzhong City, Shanxi Province, China [1]. - The sales revenue for "An Gong Niu Huang Wan" in Chinese urban and county-level public hospitals and online pharmacies is reported to be RMB 498,242 million for 2024 [2]. Group 2: Market Impact - The approval of the registration certificate is expected to help the company expand its overseas market operations and improve its market competitiveness [3]. - The impact on the company's current performance is not expected to be significant [3].

关于控股子公司收到澳门中成药注册证明书的公告 证券代码：600771 证券简称：广誉远 编号：临 2025-022 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司 制药厂：山西广誉远国药有限公司 制药厂地址：中国山西省晋中市太谷区广誉远路 1 号 二、药品的其他相关信息 山西广誉远于 2025 年 5 月 7 日向澳门特别行政区政府药物监督管理局递交了安宫 牛黄丸〔广誉远〕药品注册申请。 安宫牛黄丸是我国传统中药的经典名方，出自清代温病学家吴鞠通所著的《温病条 近日，广誉远中药股份有限公司（以下简称"公司"）控股子公司山西广誉远国药 有限公司（以下简称"山西广誉远"）收到澳门特别行政区政府药物监督管理局签发的 《中成药注册证明书》。现将相关情况公告如下： 一、药品基本信息 名称：安宫牛黄丸〔广誉远〕 剂型：丸剂 类别：非处方中成药 注册编号：MAC-C00298 注册持有人：运通贸易行药物产品出入口及批发商号 药品的销售受到国家政策、市场环境变化等因素影响，具有较大不确定性。敬请广 大投资者谨 ...

Core Viewpoint - Guangyuyuan (600771.SH) has received a Traditional Chinese Medicine registration certificate for its product "An Gong Niu Huang Wan" from the Macao SAR government, marking a significant step in expanding its market presence in Macao [1] Group 1: Company Developments - Guangyuyuan's subsidiary, Shanxi Guangyuyuan National Medicine Co., Ltd., submitted the registration application for "An Gong Niu Huang Wan" on May 7, 2025 [1] - The product is recognized as a classic formula in traditional Chinese medicine, attributed to the Qing dynasty physician Wu Jutong [1] Group 2: Product Information - "An Gong Niu Huang Wan" is indicated for treating heat diseases, including high fever, convulsions, and conditions such as stroke and encephalitis [1] - The traditional manufacturing technique of "An Gong Niu Huang Wan" has been included in the national intangible cultural heritage list [1]